@article{dd7d4328fc354ab2980da718c0c25e1e,
title = "Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results",
author = "Wykoff, \{Charles C.\}",
note = "Funding Information: Financial Disclosure(s): The author(s) have made the following disclosure(s): C.C.W.: Research support ? Adverum, Allergan, Apellis, Clearside, Genentech, Novartis, Ophthotech, Opthea, Regeneron, Regenxbio, Roche, Samsung, Santen; Consulting ? Alimera, Allegro, Allergan, Apellis, Bayer, Clearside, EyePoint, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, PolyPhotonix, RecensMedical, Roche, Regeneron, Regenxbio, Santen, Takeda; Speaker ? Regeneron. Obtained funding: Wykoff Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = nov,
doi = "10.1016/j.oret.2019.07.007",
language = "English (US)",
volume = "3",
pages = "917--919",
journal = "Ophthalmology Retina",
issn = "2468-6530",
publisher = "Elsevier",
number = "11",
}